BioMarin Pharmaceutical (BMRN) has quietly slipped about 20% this year, which is drawing more attention from investors than any single headline. With revenue and net income still growing, the pullback ...
Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks to buy according to Wall Street analysts. On ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the cheap healthcare stocks to buy heading into 2026. As reported by ...
Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...
We came across a bullish thesis on BioMarin Pharmaceutical Inc. on Value investing subreddit by BearWithMeGM. In this article ...
Fintel reports that on December 3, 2025, Leerink Partners downgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN ...
A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 9.7% in that ...
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
18d
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
What if you'd invested in Catalyst Pharmaceutical (CPRX) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investm ...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin ...
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback